Calithera Biosciences (CALA) Stock Forecast, Price Target & Predictions
CALA Stock Forecast
Calithera Biosciences stock forecast is as follows: an average price target of $2.00 (represents a 28471.43% upside from CALA’s last price of $0.01) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
CALA Price Target
The average price target for Calithera Biosciences (CALA) is $2.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 28471.43% upside from CALA's last price of $0.01.
CALA Analyst Ratings
According to 3 Wall Street analysts, Calithera Biosciences's rating consensus is 'Hold'. The analyst rating breakdown for CALA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Calithera Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2022 | - | Leerink Partners | $2.00 | $2.82 | -29.08% | 28471.43% |
The latest Calithera Biosciences stock forecast, released on Nov 15, 2022 by Leerink Partners company, set a price target of $2.00, which represents a -29.08% decrease from the stock price at the time of the forecast ($2.82), and a 28471.43% increase from CALA last price ($0.01).
Calithera Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.01 | $0.01 | $0.01 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Calithera Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Calithera Biosciences's last price of $0.01. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2022 | SVB Leerink | - | Market Perform | Downgrade |
| Aug 29, 2022 | H.C. Wainwright | - | Buy | Upgrade |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Downgrade |
Calithera Biosciences's last stock rating was published by SVB Leerink on Nov 15, 2022. The company Downgrade its CALA rating from "null" to "Market Perform".
Calithera Biosciences Financial Forecast
Calithera Biosciences Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $6.75M | $3.00M | - | $17.07M | $5.19M | $7.25M | $7.25M | $4.19M | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | $8.51M | $3.29M | $9.10M | $3.52M | $17.12M | $60.68M | $4.49M | $9.39M | $6.29M | $2.67M | $108.00K | $78.47K | $67.79K |
| High Forecast | - | - | - | - | - | - | - | - | - | $10.21M | $3.95M | $10.92M | $4.23M | $20.54M | $72.81M | $5.39M | $11.27M | $7.55M | $3.20M | $129.60K | $94.17K | $81.34K |
| Low Forecast | - | - | - | - | - | - | - | - | - | $6.81M | $2.63M | $7.28M | $2.82M | $13.69M | $48.54M | $3.59M | $7.51M | $5.03M | $2.13M | $86.40K | $62.78K | $54.23K |
| # Analysts | - | - | - | - | - | - | - | - | - | 16 | 15 | 18 | 8 | 8 | 14 | 8 | 20 | 15 | 15 | 18 | 19 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.74% | 0.85% | - | 0.28% | 1.16% | 0.77% | 1.15% | 1.57% | - | - | - |
Calithera Biosciences's average Quarter revenue forecast for Jun 22 based on 15 analysts is $3.29M, with a low forecast of $2.63M, and a high forecast of $3.95M. CALA's average Quarter revenue forecast represents a -51.22% decrease compared to the company's last Quarter revenue of $6.75M (Sep 21).
Calithera Biosciences EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 16 | 15 | 18 | 8 | 8 | 14 | 8 | 20 | 15 | 15 | 18 | 19 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | $-7.45M | $-9.01M | $-13.54M | $-11.08M | $-14.23M | $-18.72M | $-2.95M | $-13.08M | $-5.98M | $-5.11M | $-5.51M | $-8.47M | $-10.29M | $-9.50M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | $-13.96M | $-15.62M | $-14.94M | $-16.71M | $-13.57M | $-4.56M | $-11.04M | $-7.34M | $-4.32M | $-17.70M | $-10.15M | $-9.78M | $-8.55M |
| High Forecast | - | - | - | - | - | - | - | - | - | $-11.17M | $-12.50M | $-11.95M | $-13.37M | $-10.85M | $-3.65M | $-8.83M | $-5.87M | $-3.46M | $-14.16M | $-8.12M | $-7.82M | $-6.84M |
| Low Forecast | - | - | - | - | - | - | - | - | - | $-16.76M | $-18.75M | $-17.92M | $-20.05M | $-16.28M | $-5.48M | $-13.25M | $-8.81M | $-5.19M | $-21.24M | $-12.18M | $-11.73M | $-10.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.65% | 0.87% | 0.74% | 0.85% | 1.38% | 0.65% | 1.19% | 0.81% | 1.18% | 0.31% | 0.84% | 1.05% | 1.11% |
undefined analysts predict CALA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Calithera Biosciences's previous annual EBITDA (undefined) of $NaN.
Calithera Biosciences Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 16 | 15 | 18 | 8 | 8 | 14 | 8 | 20 | 15 | 15 | 18 | 19 | 15 |
| Net Income | - | - | - | - | - | - | - | - | $14.12M | $-10.08M | $10.22M | $-11.17M | $-14.31M | $-18.85M | $-3.08M | $-13.21M | $-6.07M | $-5.19M | $-5.59M | $-8.54M | $-10.36M | $-9.58M |
| Avg Forecast | $-15.11M | $-15.11M | $-15.11M | $-15.11M | $-1.40M | $-1.35M | $-1.40M | $-2.60M | $-7.44M | $-14.08M | $-15.71M | $-15.06M | $-16.80M | $-13.19M | $-4.76M | $-11.14M | $-7.45M | $-4.39M | $-17.96M | $-10.13M | $-9.76M | $-8.56M |
| High Forecast | $-15.11M | $-15.11M | $-15.11M | $-15.11M | $-1.40M | $-1.35M | $-1.40M | $-2.60M | $-7.44M | $-11.26M | $-12.57M | $-12.05M | $-13.44M | $-10.56M | $-3.81M | $-8.91M | $-5.96M | $-3.52M | $-14.37M | $-8.10M | $-7.81M | $-6.85M |
| Low Forecast | $-15.11M | $-15.11M | $-15.11M | $-15.11M | $-1.40M | $-1.35M | $-1.40M | $-2.60M | $-7.44M | $-16.89M | $-18.85M | $-18.07M | $-20.16M | $-15.83M | $-5.71M | $-13.37M | $-8.94M | $-5.27M | $-21.55M | $-12.15M | $-11.71M | $-10.28M |
| Surprise % | - | - | - | - | - | - | - | - | -1.90% | 0.72% | -0.65% | 0.74% | 0.85% | 1.43% | 0.65% | 1.19% | 0.81% | 1.18% | 0.31% | 0.84% | 1.06% | 1.12% |
Calithera Biosciences's average Quarter net income forecast for Mar 23 is $-2.60M, with a range of $-2.60M to $-2.60M. CALA's average Quarter net income forecast represents a -118.38% decrease compared to the company's last Quarter net income of $14.12M (Dec 22).
Calithera Biosciences SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 16 | 15 | 18 | 8 | 8 | 14 | 8 | 20 | 15 | 15 | 18 | 19 | 15 |
| SG&A | - | - | - | - | - | - | - | - | $2.58M | $3.08M | $3.62M | $6.34M | $4.49M | $3.09M | $3.50M | $3.51M | $3.07M | $2.85M | $3.31M | $2.32M | $2.67M | $2.59M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | $7.99M | $3.78M | $8.55M | $4.04M | $2.16M | $5.41M | $2.96M | $3.77M | $2.41M | $3.06M | $123.94K | $90.06K | $77.80K |
| High Forecast | - | - | - | - | - | - | - | - | - | $9.59M | $4.53M | $10.26M | $4.85M | $2.59M | $6.49M | $3.55M | $4.53M | $2.89M | $3.67M | $148.73K | $108.07K | $93.35K |
| Low Forecast | - | - | - | - | - | - | - | - | - | $6.40M | $3.02M | $6.84M | $3.23M | $1.73M | $4.33M | $2.37M | $3.02M | $1.93M | $2.45M | $99.16K | $72.05K | $62.23K |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.39% | 0.96% | 0.74% | 1.11% | 1.43% | 0.65% | 1.19% | 0.81% | 1.18% | 1.08% | 18.71% | 29.59% | 33.31% |
Calithera Biosciences's average Quarter SG&A projection for Mar 23 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CALA last annual SG&A of $2.58M (Dec 22).
Calithera Biosciences EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 16 | 15 | 18 | 8 | 8 | 14 | 8 | 20 | 15 | 15 | 18 | 19 | 15 |
| EPS | - | - | - | - | - | - | - | - | $3.05 | $-2.07 | $2.10 | $-3.01 | $-3.86 | $-10.36 | $-1.71 | $-7.38 | $-3.42 | $-2.94 | $-4.42 | $-8.76 | $-10.91 | $-10.42 |
| Avg Forecast | $-3.03 | $-3.03 | $-3.03 | $-3.03 | $-0.28 | $-0.27 | $-0.28 | $-0.52 | $-1.49 | $-1.93 | $1.15 | $1.25 | $1.01 | $-5.60 | $-9.90 | $-5.40 | $-5.40 | $-2.20 | $9.00 | $-12.80 | $-9.80 | $-8.40 |
| High Forecast | $-3.03 | $-3.03 | $-3.03 | $-3.03 | $-0.28 | $-0.27 | $-0.28 | $-0.52 | $-1.49 | $-1.93 | $1.15 | $1.25 | $1.01 | $-4.48 | $-7.92 | $-4.32 | $-4.32 | $-1.76 | $10.80 | $-10.24 | $-7.84 | $-6.72 |
| Low Forecast | $-3.03 | $-3.03 | $-3.03 | $-3.03 | $-0.28 | $-0.27 | $-0.28 | $-0.52 | $-1.49 | $-1.93 | $1.15 | $1.25 | $1.01 | $-6.72 | $-11.88 | $-6.48 | $-6.48 | $-2.64 | $7.20 | $-15.36 | $-11.76 | $-10.08 |
| Surprise % | - | - | - | - | - | - | - | - | -2.05% | 1.07% | 1.82% | -2.42% | -3.82% | 1.85% | 0.17% | 1.37% | 0.63% | 1.34% | -0.49% | 0.68% | 1.11% | 1.24% |
According to 0 Wall Street analysts, Calithera Biosciences's projected average Quarter EPS for Mar 23 is $-0.52, with a low estimate of $-0.52 and a high estimate of $-0.52. This represents a -117.05% decrease compared to CALA previous annual EPS of $3.05 (Dec 22).
Calithera Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CALA | Calithera Biosciences | $0.01 | $2.00 | 19900.00% | Hold |
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| KOD | Kodiak Sciences | $3.90 | $31.60 | 710.26% | Buy |
| CKPT | Checkpoint Therapeutics | $3.49 | $20.00 | 473.07% | Buy |
| ADAP | Adaptimmune Therapeutics | $0.83 | $2.83 | 240.96% | Buy |
| PDSB | PDS Bio | $3.23 | $9.00 | 178.64% | Buy |
| AFMD | Affimed | $3.27 | $7.50 | 129.36% | Buy |
| VSTM | Verastem | $3.90 | $8.33 | 113.59% | Buy |
| ADVM | Adverum Bio | $7.54 | $15.50 | 105.57% | Buy |
| MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
| GLMD | Galmed Pharmaceuticals | $3.24 | $5.00 | 54.32% | Buy |
| LPTX | Leap Therapeutics | $3.67 | $5.50 | 49.86% | Buy |
| ARDX | Ardelyx | $5.89 | $8.75 | 48.56% | Buy |
| ZURA | Zura Bio | $4.37 | $5.00 | 14.42% | Buy |
| ABEO | Abeona Therapeutics | $6.04 | $6.00 | -0.66% | Buy |
CALA Forecast FAQ
Is Calithera Biosciences a good buy?
No, according to 3 Wall Street analysts, Calithera Biosciences (CALA) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of CALA's total ratings.
What is CALA's price target?
Calithera Biosciences (CALA) average price target is $2 with a range of $2 to $2, implying a 28471.43% from its last price of $0.007. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Calithera Biosciences stock go up soon?
According to Wall Street analysts' prediction for CALA stock, the company can go up by 28471.43% (from the last price of $0.007 to the average price target of $2), up by 28471.43% based on the highest stock price target, and up by 28471.43% based on the lowest stock price target.
Can Calithera Biosciences stock reach $0?
CALA's average twelve months analyst stock price target of $2 supports the claim that Calithera Biosciences can reach $0 in the near future.
What are Calithera Biosciences's analysts' financial forecasts?
Calithera Biosciences's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-6.739M (high $-6.739M, low $-6.739M), average SG&A $0 (high $0, low $0), and average EPS is $-1.35 (high $-1.35, low $-1.35). CALA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-60.457M (high $-60.457M, low $-60.457M), average SG&A $0 (high $0, low $0), and average EPS is $-12.111 (high $-12.111, low $-12.111).
Did the CALA's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Sep 2021), Calithera Biosciences's revenue was $6.75M, missing the average analysts' forecast of $9.1M by -25.81%. The company's EBITDA was $-11.081M, missing the average prediction of $-14.935M by -25.81%. Calithera Biosciences's net income was $-11.172M, missing the average estimation of $-15.058M by -25.81%. The company's SG&A was $6.34M, missing the average forecast of $8.55M by -25.81%. Lastly, the company's EPS was $-3.015, missing the average prediction of $1.25 by -342.09%